相关实验视频
Updated: Jun 9, 2025

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.2K
晚期心力衰竭中的置换疗法:时间,方法和临床考虑
Ramzi Ibrahim1, Chelsea Takamatsu1, Abdulla Alabagi1
1Department of Medicine, University of Arizona, Tucson, AZ.
Journal of cardiac failure
|October 25, 2024
概括
晚期心力衰竭 (HF) 中的急性功能障碍影响治疗结果和治疗决策. 本综述探讨了为这些复杂患者优化替代疗法 (KRTs).
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
背景情况:
- 急性功能障碍经常复杂化晚期心力衰竭 (HF),显著恶化预后和生存率.
- 这种功能障碍影响了关键的治疗决策,包括左心室辅助器件 (LVAD) 植入和心脏移植的资格.
- 置换疗法 (KRTs) 是至关重要的,但需要对时间,模式选择和患者特定因素进行谨慎管理.
研究的目的:
- 审查在高级HF患者中实施KRT的复杂性.
- 为优化KRT模式的时间和选择提供指导.
- 讨论在管理这种患者群体时遇到的独特临床挑战.
主要方法:
- 这是一个复习文章.
- 在高级高频中对KRT进行文献搜索和综合.
- 讨论临床决策框架.
主要成果:
- 在高级HF中,KRT对于管理急性功能障碍至关重要.
- 对KRT的最佳时间和模式选择对于患者的治疗结果至关重要.
- 个性化患者评估是成功实施KRT的关键.
结论:
- 通过KRT有效管理功能障碍,可以改善晚期HF的结果.
- 仔细考虑KRT时间,模式和患者因素至关重要.
- 对针对先进高频的定制KRT策略进行进一步的研究是有必要的.
相关概念视频
Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1
Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Dialysis
272
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
272
Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527

